The Myeloma Beacon In fact, they have approached nearly 100 percent for some three-drug combinations involving one or more novel agents, including cyclophosphamide (Cytoxan), Velcade, and dexamethasone (CyBorD, or VCD) (see related Beacon news), and Velcade, ...
MedPage Today Most hospitalized patients with cancer for the duration of stay; Multiple myeloma patients on anti-angiogenesis agents with chemotherapy or dexamethasone or both (low-molecular-weight heparin or low-dose aspirin); Major cancer surgery, starting before ... and more »
MarketWatch The trial evaluated use of oral pomalidomide plus low-dose dexamethasone (n=302) compared with high-dose dexamethasone (n=153) in patients with relapsed and refractory multiple myeloma; according to the protocol, all patients were to have been ...
Motley Fool The most significant new information related to progression-free survival and overall survival rates. Celgene announced that patients taking Pomalyst with low-dose dexamethasone achieved a median progression-free survival rate of 4 months and a median ... and more »
EON: Enhanced Online News (press release) In the study, presented by Katja Weisel, M.D., Department of Medicine, University Hospital Tübingen, Tübingen, Germany, 455 pat...
MarketWatch (press release) BEDFORD, Mass., Jun 03, 2013 (BUSINESS WIRE) -- Ocular Therapeutix, Inc. announced today it has completed enrollment for its sustained release dexamethasone (OTX-DP) in a Phase II study under an Investigational New Drug (IND) submission to the ...
